The Paraprotein - an Enduring Biomarker
- PMID: 30828116
- PMCID: PMC6370287
The Paraprotein - an Enduring Biomarker
Abstract
The 'paraprotein', also known as M-protein, monoclonal protein and monoclonal component, has stood the test of time as the key biomarker in monoclonal gammopathies. It continues to reinvent itself as new electrophoretic and immunoassay methods are developed that are analytically more sensitive. Use of the serum free light chain immunoassay in particular has led to new clinical discoveries and improvements in the diagnosis and monitoring of patients with plasma cell dyscrasia and other monoclonal gammopathies. In addition, minimal residual disease can be detected using mass spectrometry and flow cytometry methods.
Conflict of interest statement
Competing Interests: None declared.
References
-
- Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016;54:907–19. - PubMed
-
- Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292–5. - PubMed
-
- Leung N, Barnidge DR, Hutchison CA. Laboratory testing in monoclonal gammopathy of renal significance (MGRS) Clin Chem Lab Med. 2016;54:929–37. - PubMed
-
- Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol. 2000;111:1035–44. - PubMed
-
- von Rustizky J. Multiple myelom. Deutsche Zeitschrift für Chirurgie. 1873;3:162–72.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources